The Effect of Prolonged Glucosamine Usage on HbA1c Levels and New-Onset Diabetes Mellitus in Overweight and Obese Middle-Aged Women

Gommans, Yvonne M.M.; Runhaar, Jos; Jacobs, M. L.; Bierma-Zeinstra, Sita M A

doi:10.1016/j.amjmed.2016.11.038

Cited by 9 publications

(13 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…61 In this sense, however, a large RCT comprising 407 overweight and obese women, followed up for 2.5 years, reported that there was no significant effect of a 2.5-year GS intervention on mean glycosylated haemoglobin level. 62 Present data, although limited by the narrative nature of the review, confirmed that GS is safe from a metabolic point of view, being in agreement with a large longitudinal study using the UK Biobank showing that the use of GS in OA is associated with a lower incidence of diabetes, over 8 years of follow up. 63 In the same database, it is reported that GS can lead to a reduction in cardiovascular disease 64 and all-cause and specific-cause mortality.…”

Section: Authorsupporting

confidence: 85%

Glucosamine sulphate: an umbrella review of health outcomes

Veronese

Demurtas

Smıth

et al. 2020

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Background and Aims: Glucosamine sulphate (GS) can be used as background therapy in people affected by knee osteoarthritis (OA). Knowledge regarding the efficacy and safety of GS is of importance since its use worldwide is increasing. Therefore, the present study aimed to map and grade the diverse health outcomes associated with GS using an umbrella review approach. Methods: Medline, Cinahl and Embase databases were searched until 1 April 2020. An umbrella review of systematic reviews and meta-analyses of randomized controlled trials (RCTs) was carried out. The evidence from the RCTs was graded using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool. Results: From 140 articles returned, 11 systematic reviews, for a total of 21 outcomes (37 RCTs; 3949 participants; almost all using 1500 mg/day), were included. No systematic reviews/meta-analyses of observational studies were included. Regarding the findings of the meta-analyses, 9/17 outcomes were statistically significant, indicating that GS is more effective than placebo. A high certainty of evidence, as assessed by GRADE, supported the use of GS ( versus placebo) in improving the Lequesne Index, joint space width change, joint space width change after 3 years of follow up, joint space narrowing and OA progression. No difference in terms of adverse effects was found between GS and placebo. In systematic reviews, GS was associated with a better glucose profile and a better physical function performance than placebo. Conclusion: GS, when used as a prescription drug (i.e. crystalline glucosamine sulphate) at 1500 mg daily dosage, can positively affect the cartilage structure, reduce pain, improve function and glucose metabolism in people with knee OA, without having a greater incidence of adverse effects than placebo.

show abstract

Section: Authorsupporting

confidence: 85%

Glucosamine sulphate: an umbrella review of health outcomes

Veronese

Demurtas

Smıth

et al. 2020

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

show abstract

“…In addition, a meta-analysis on the effects of glucosamine on glucose metabolism found that glucosamine, at the usual oral doses used in knee OA patients, is well-tolerated by normal, diabetic, or pre-diabetic patients [56]. In the PROOF trial, a non-significant increase in glycated hemoglobin levels was found in overweight women who received pCGS during the follow-up period [57,58]. Thus, the SEAWG recommends to advise caution at the start of treatment with glucosamine in diabetic patients [59].…”

Section: Sysadoasmentioning

confidence: 99%

2019 revised algorithm for the management of knee osteoarthritis: the Southeast Asian viewpoint

et al. 2021

View full text Add to dashboard Cite

Background Since 2014, the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) algorithm for the management of knee osteoarthritis (OA) is available worldwide. Aim Based on this document, a Southeast Asia Working Group (SEAWG) wished to see how the new ESCEO algorithm developed in 2019 was perceived by Southeast Asian experts and how it was integrated into their clinical practice. Methods A SEAWG was set up between members of the international ESCEO task force and a group of Southeast Asian experts. Results Non-pharmacological management should always be combined with pharmacological management. In step 1, symptomatic slow-acting drugs for osteoarthritis are the main background therapy, for which high-quality evidence is available only for the formulations of patented crystalline glucosamine sulfate and chondroitin sulfate. In step 2, oral NSAIDs are a useful option, considering the cardiovascular/renal/gastrointestinal profiles of the individual patient. Intra-articular hyaluronic acid and corticosteroids are a possible alternative to oral NSAIDs, but limited evidence is available. If steps 1 and 2 do not give adequate relief of symptoms, tramadol can be used, but its safety is debated. In general, the indications of the ESCEO algorithm are important in Southeast Asian countries, but the reimbursement criteria of local health systems are an important aspect for adherence to the ESCEO algorithm. Conclusion This guidance provides evidence-based and easy-to-follow advice on how to establish a treatment algorithm in knee OA, for practical implementation in clinical practice in Southeast Asian countries.

show abstract

“…20,24 Seven studies recruited only healthy subjects. 11,[15][16][17]21,22,25 Only two studies recruited osteoarthritic patients. 19,26 One study randomised the subjects according to obesity status i.e.…”

Section: Sample Size and Characteristicsmentioning

confidence: 99%

“…17 Five of the studies merely reported the mean BMI 10,15,17,18,21 from which three of the studies reflected that the subjects were mostly obese as the mean BMI was more than 30. 18,22,23 Glucosamine Dosing Six of the studies followed the recommendation of dosing in the CPG Management of Osteoarthritis 2 nd Ed 2013 11,[18][19][20]22,26 while one prospective study reported affirmative use of glucosamine but no specific information provided on the dosing. 21 Three of the studies used the recommended dose but at a shorter duration of between 14 to 42 days.…”

Section: Sample Size and Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

The Effect of Glucosamine With or Without Chondroitin Sulphate on Glucose Monitoring Parameters in Humans – A Systematic Review

Menon¹,

Hashim²,

Zainal³

et al. 2021

JYP

View full text Add to dashboard Cite

Musculoskeletal diseases that included OA was the second greatest contributor to disability as measured by years lived with disability. The goals of OA treatment are to reduce pain, improve function and quality of life and decrease disability. The objective of this systematic review is to summarise the findings of the effect of glucosamine with or without chondroitin sulphate on glucose monitoring parameters in humans. An English language literature search of electronic bibliographic databases such as Medline, Web of Science, Science Direct, Scopus and Cochrane since inception to June 2020 was conducted. Two reviewers independently analysed the studies for quality and content using the Downs and Black Checklist. The thirteen studies that were included in the review consists of randomised control trials (n=7), non-randomised control trials (n=3), prospective cohort studies (n=2) and pre-post studies (n=1). Five studies detected the effect of glucosamine on glucose parameters. Studies that recruited patients with baseline impaired glucose tolerance or insulin resistance were more likely to detect an effect on glucose metabolism. Patients taking glucosamine have a higher risk of diabetes especially those who have high baseline glucose levels or have diabetes or have impaired glucose tolerance. Only two studies investigated the effect of glucosamine on glucose parameters in patients having osteoarthritis.

show abstract

The Effect of Prolonged Glucosamine Usage on HbA1c Levels and New-Onset Diabetes Mellitus in Overweight and Obese Middle-Aged Women

Abstract: There was no effect of glucosamine sulfate on mean HbA1c level nor on obtaining a high HbA1c level or new-onset diabetes mellitus over 6.5 years, especially in participants with a normal HbA1c level at baseline.

Cited by 9 publications

References 23 publications

Glucosamine sulphate: an umbrella review of health outcomes

Glucosamine sulphate: an umbrella review of health outcomes

2019 revised algorithm for the management of knee osteoarthritis: the Southeast Asian viewpoint

The Effect of Glucosamine With or Without Chondroitin Sulphate on Glucose Monitoring Parameters in Humans – A Systematic Review

Contact Info

Product

Resources

About